Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | HB0045 |
Synonyms | |
Therapy Description |
HB0045 is a combination of two anti-CD73 monoclonal antibodies, HB0039 and HB0039, which potentially reduces immunosuppression, leading to enhanced antitumor immune response and inhibition of tumor growth (PMID: 39738003). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
HB0045 | HB-0045|HB 0045 | CD73 Antibody 13 | HB0045 is a combination of two anti-CD73 monoclonal antibodies, HB0039 and HB0039, which potentially reduces immunosuppression, leading to enhanced antitumor immune response and inhibition of tumor growth (PMID: 39738003). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06056323 | Phase Ib/II | HB0045 | A Study of HB0045 Injection in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |